Helen Tesfaye

Dec 11, 2024 | jamanetwork.com | Helen Tesfaye |Julie M. Paik |Miin Roh |Phyo T. Htoo

Empagliflozin and the Risk of Retinopathy in Patients With Type 2 Diabetes Key PointsQuestion  Is there an association between empagliflozin and the risk of nonproliferative diabetic retinopathy (NPDR) and diabetic retinopathy (DR) progression in patients with type 2 diabetes (T2D)?

May 28, 2024 | jamanetwork.com | Po-Ren Hsiao |James Cheng-Chung Wei |Julie M. Paik |Helen Tesfaye

Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Nephrolithiasis in Clinical Practice SGLT2 Inhibitors and Nephrolithiasis Risk in Type 2 Diabetes Julie M. Paik, MD, ScD, MPH; Helen Tesfaye, PharmD, MSc; Gary C. Curhan, MD, ScD; Heidi Zakoul, BA; Deborah J. Wexler, MD, MSc; Elisabetta Patorno, MD, DrPH Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Nephrolithiasis in Clinical Practice—Reply Julie M.

Jan 29, 2024 | jamanetwork.com | Julie M. Paik |Helen Tesfaye |Gary Curhan |Heidi Zakoul

Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes Key PointsQuestion  What is the association between sodium-glucose cotransporter 2 inhibitors (SGLT2is) and risk of developing nephrolithiasis in patients with type 2 diabetes?

Nov 1, 2023 | bmjopen.bmj.com | Julie C. Lauffenburger |Helen Tesfaye |Daniel Solomon |Elliott Antman

DiscussionIn adults initiating medications for hypertension, diabetes and hyperlipidaemia, we found that adherence was poor and that almost 15% of patients never filled a medication for their condition again after filling the first time over a 1-year follow-up.